Predictive Factors of Left Ventricular Mass Changes after Treatment of Primary Aldosteronism

Abstract

A variety of abnormalities that occur in patients with primary aldosteronism indicate the capability of elevated aldosterone to induce cardiac damage over that induced by hypertension itself. This study investigates factors that can predict structural and functional changes of the heart after treatment of primary aldosteronism in a post-hoc analysis of 54 patients who were enrolled in a long-term follow-up study that was conducted after either adrenalectomy or treatment with spironolactone. Cardiac ultrasound assessment was performed before treatment and after with an average follow-up of 6.4 years. During follow-up, blood pressure decreased significantly and comparably in both treatment groups. In both treatment groups, left ventricular mass decreased significantly with a trend to improved diastolic filling profile and no changes in ventricular geometry. At univariate analysis, changes in left ventricular mass induced by treatment of primary aldosteronism were directly related with changes in systolic blood pressure and pretreatment plasma aldosterone levels measured both at baseline and after an intravenous saline load. This relationship was maintained when patients treated with adrenalectomy and spironolactone were analyzed separately. Multivariate regression analysis showed that changes in systolic blood pressure and pretreatment aldosterone levels were independent predictors of left ventricular mass changes after treatment. This study strongly supports a role of aldosterone in promoting left ventricular hypertrophy that is independent of the hypertension-related hemodynamic load and suggests a practical way to predict left ventricular mass changes following surgical and medical treatment of primary aldosteronism.

Key words

adrenalectomy - diastolic function - echocardiography - left ventricular hypertrophy - spironolactone

• References

• 1 Rossi GP, Sechi LA, Giacchetti G, Ronconi V, Strazzullo P, Funder JW. Primary aldosteronism: cardiovascular, renal, and metabolic implications. Trends Endocrinol Metab 2008; 19: 88-90
• 2 Sechi LA, Colussi GL, Di Fabio A, Catena C. Cardiovascular and renal damage in primary aldosteronism: outcomes after treatment. Am J Hypertens 2010; 12: 1253-1260
• 3 Milliez P, Girerd X, Plouin PF, Blacher J, Safar ME, Mourad JJ. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J Am Coll Cardiol 2005; 45: 1243-1248
• 4 Catena C, Colussi G, Nadalini E, Chiuch A, Baroselli S, Lapenna R, Sechi LA. Cardiovascular outcomes in patients with primary aldosteronism after treatment. Arch Intern Med 2008; 168: 80-85
• 5 Born-Frontsberg E, Reincke M, Rump LC, Hahner S, Diederich S, Lorenz R, Allolio B, Seufert J, Schirpenbach C, Beuschlein F, Bidlingmaier M, Endres S, Quinkler M. Participants of the German Conn’s Registry . Cardiovascular and cerebrovascular comorbidities of hypokalemic and normokalemic primary aldosteronism: results of the German Conn’s Registry. J Clin Endocrinol Metab 2009; 94: 1125-1130
• 6 Rossi GP, Sacchetto A, Pavan E, Palatini P, Gramero GR, Pessina AC. Remodeling of the left ventricle in primary aldosteronism due to Conn’s adenoma Circulatron. 1997; 95 (6) 1471-1478
• 7 Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatini P, Pessina AC. Changes in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 1996; 27: 1039-1045
• 8 Rossi GP, Di Bello V, Ganzaroli C, Sacchetto A, Cesari M, Bertini A, Giorgi D, Scognamiglio R, Mariani M, Pessina AC. Excess aldosterone is associated with alterations of myocardial texture in primary aldosteronism. Hypertension 2002; 40: 23-27
• 9 Strauch B, Petrák O, Wichterle D, Zelinka T, Holaj R, Widimsky Jr J. Increased arterial wall stiffness in primary aldosteronism in comparison with essential hypertension. Am J Hypertens 2006; 19: 909-914
• 10 Holaj R, Zelinka T, Wichterle D, Petrák O, Strauch B, Widimsky Jr J. Increased intima-media thickness of the common carotid artery in primary aldosteronism in comparison with essential hypertension. J Hypertens 2007; 25: 1451-1457
• 11 Rizzoni D, Muiesan ML, Porteri E, Salvetti M, Castellano M, Bettoni G, Tiberio G, Giulini SM, Monteduro C, Garavelli G, Agabiti-Rosei E. Relations between cardiac and vascular structure in patients with primary and secondary hypertension. J Am Coll Cardiol 1998; 32: 985-992
• 12 Muiesan ML, Salvetti M, Paini A, Agabiti-Rosei C, Monteduro C, Galbassini G, Belotti E, Aggiusti C, Rizzoni D, Castellano M, Agabiti-Rosei E. Inappropriate left ventricular mass in patients with primary aldosteronism. Hypertension 2008; 52: 529-534
• 13 Catena C, Colussi G, Lapenna R, Nadalini E, Chiuch A, Gianfagna P, Sechi LA. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 2007; 50: 911-918
• 14 Cicala M, Cesari M, Patalano A, Iacobone M, Mariniello B, Mantero F. Treatment of primary aldosteronism: short and middle-term effects of medical and surgical therapy in primary hyperaldosteronism: experience of 45 cases. J Hypertens 2010; 28 ((e-Supplement A)) 305
• 15 Casale PN, Devereux RB, Milner M, Zullo G, Harshfield GA, Pickering TG, Laragh JH. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive men. Ann Intern Med 1986; 105: 173-176
• 16 Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Catena C. Long-term renal outcomes in patients with primary aldosteronism. JAMA 2006; 295: 2638-2645
• 17 Devereux RB, Roman MJ. Evaluation of cardiac and vascular structure by echocardiography and other noninvasive techniques. In: Laragh JH, Brenner BM. (eds.). Hypertension: Pathophysiology, Diagnosis, Treatment. 2^nd ed. New York, NY: Raven Press; 1995: 1969-1985
• 18 Quinones MA, Otto C, Stoddard M, Waggoner A, Zoghbi W. Recommendations for quantifications of Doppler echocardiography: a report from the Doppler quantification Task Force for the Nomenclature and Standards Committee of the American Society of Echocardiography. J Am Soc Echocardiogr 2002; 15: 167-184
• 19 Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, Vargiu P, Simongini I, Laragh JH. Patterns of left ventricular hypertrophy and geometric remodeling in arterial hypertension. J Am Coll Cardiol 1992; 19: 1550-1558
• 20 De Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O, Alderman MH. Left ventricular mass and body size in normotensive children and adults: assessment of allometric relations and of the impact of overweight. J Am Coll Cardiol 1992; 20: 1251-1260
• 21 Denolle T, Chatellier G, Julien J, Battaglia C, Luo P, Plouin PF. Left ventricular mass and geometry before and after etiologic treatment in renovascular hypertension, aldosterone-producing adenoma, and pheochromocytoma. Am J Hypertens 1993; 6: 907-913
• 22 Goldkorn R, Yurenev A, Blumenfeld J, Fishman D, Devereux RB. Echocardiographic comparison of left ventricular structure and function in hypertensive patients with primary aldosteronism. Am J Hypertens 2002; 15: 340-345
• 23 Morgan HE, Baker KM. Cardiac hypertrophy: mechanical, neural, and endocrine dependance. Circulation 1991; 83: 13-25
• 24 Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R, Pessina A, Porcellati C, Rappelli A, Salvetti A, Trimarco B. Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. Circulation 1997; 95: 1464-1470